# Church & Dwight Co Inc: Form 10-Q for the period ended Sep 30, 2012

- Company: [Church & Dwight Co Inc](/companies/chd.md) (CIK 313927)
- Form: 10-Q
- Filed: 2012-11-05
- Accepted by EDGAR: Nov 5, 2012, 19:47 ET
- Period: 2012-09-30
- Accession: 0001193125-12-451493
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/313927/000119312512451493/d417286d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/313927/000119312512451493/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2012-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2012-07-01 to 2012-09-30 | $725.2m | us-gaap:SalesRevenueGoodsNet |
| Revenue | 9 months, 2012-01-01 to 2012-09-30 | $2.11bn | us-gaap:SalesRevenueGoodsNet |
| Cost of revenue | 3 months, 2012-07-01 to 2012-09-30 | $397.7m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2012-01-01 to 2012-09-30 | $1.18bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2012-07-01 to 2012-09-30 | $327.5m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2012-01-01 to 2012-09-30 | $933.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2012-07-01 to 2012-09-30 | $13.7m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2012-01-01 to 2012-09-30 | $40.2m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2012-07-01 to 2012-09-30 | $89.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2012-01-01 to 2012-09-30 | $273.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2012-07-01 to 2012-09-30 | $145.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2012-01-01 to 2012-09-30 | $410.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2012-07-01 to 2012-09-30 | $2.6m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2012-01-01 to 2012-09-30 | $7.7m | us-gaap:InterestExpense |
| Income tax | 3 months, 2012-07-01 to 2012-09-30 | $52.1m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2012-01-01 to 2012-09-30 | $143.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2012-07-01 to 2012-09-30 | $93.9m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2012-01-01 to 2012-09-30 | $269.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.66 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2012-01-01 to 2012-09-30 | $1.88 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2012-07-01 to 2012-09-30 | $0.67 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2012-01-01 to 2012-09-30 | $1.92 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2012-07-01 to 2012-09-30 | 142,200,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2012-01-01 to 2012-09-30 | 143,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2012-01-01 to 2012-09-30 | $315.9m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2012-01-01 to 2012-09-30 | $49.7m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2012-01-01 to 2012-09-30 | $101.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months, 2012-01-01 to 2012-09-30 | $200.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2012-09-30 | $241.2m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2012-09-30 | $1.44bn | us-gaap:AssetsCurrent |
| Total assets | at 2012-09-30 | $3.84bn | us-gaap:Assets |
| Current liabilities | at 2012-09-30 | $652.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2012-09-30 | $1.78bn | us-gaap:Liabilities |
| Long-term debt | at 2012-09-30 | $649.4m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | at 2012-09-30 | $254.4m | us-gaap:ShortTermBorrowings |
| Shareholders' equity | at 2012-09-30 | $2.06bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 30,414 characters.

### Recent Developments

#### Avid Health Acquisition

On October 1, 2012, the Company acquired all of the issued and outstanding capital stock of Avid Health, Inc. (“Avid Health”). Avid Health is a leader in the vitamin, mineral, and supplement category. Its products, among others, include L’IL CRITTERS children’s gummy vitamins and VITAFUSION adult gummy vitamins. The total purchase price was approximately $650 million, which is subject to adjustment based on the closing working capital of Avid Health and its subsidiaries. The Company financed the acquisition with a combination of proceeds from an underwritten public offering of $400 million aggregate principal amount of 2.875% Senior Notes due 2022, the issuance of commercial paper and cash.

The proceeds from the financings were deposited into an escrow account on September 26, 2012. These funds held in escrow were reported as “Cash held in escrow” in the accompanying condensed consolidated balance sheet as of September 30, 2012. Upon closing of the transaction on October 1, 2012, these funds were released from escrow and paid to the seller parties as purchase price and used to pay certain obligations of Avid Health. In addition, a portion of the purchase price was deposited into a separate escrow account and serves as security for certain seller obligations with respect to purchase price adjustments and indemnity obligations, as set forth in the stock purchase agreement filed by the Company as an exhibit to its Current Report on Form 8-K filed on August 20, 2012.

Avid Health’s annual sales are approximately $230 million. The Company anticipates that the Avid Health brands will be managed principally within the Consumer Domestic segment.

#### Share Repurchase Authorization

On October 31, 2012, the Company’s Board of Directors authorized a new share repurchase program, under which the Company may purchase up to an additional $300 million of the Company’s common stock. The previous authorization announced in August 2011 has approximately $20 million remaining for use in the repurchase of the Company’s shares. Under the new program, shares may be repurchased from time to time in the open market, in privately negotiated transactions or otherwise, subject to market conditions, and corporate and legal requirements. There is no expiration date on the stock repurchase authorization and the Company is not obligated to acquire any specific number of shares. As of October 30, 2012, approximately 140 million shares of the Company’s common stock were outstanding.

#### Hurricane Sandy

As a result of Hurricane Sandy, certain of the Company’s operations and the operations of certain of its customers and suppliers, including third party information technology service providers, were affected by the loss of electricity and other disruptions to our and their businesses. While we are currently unable to quantify the financial impact of such losses and disruptions, it is possible that they could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.

### Results of Operations

#### Consolidated results

#### Net Sales

Net sales for the quarter ended September 30, 2012 were $725.2 million, an increase of $24.2 million or 3.5% over the third quarter of 2011. Net sales for the nine months ended September 30, 2012 were $2,112.2 million, an increase of $94.0 million or 4.7% over the comparable nine month period in 2011. The components of the net sales increase are the following:

| Net Sales - Consolidated | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 |
| --- | ---: | ---: |
| Product volumes sold | 4.5% | 7.0% |
| Pricing / Product mix | 0.1% | (1.5%) |
| Foreign exchange rate fluctuations | (1.2%) | (1.1%) |
| Acquired product lines (1) | 0.3% | 0.8% |
| Sales in anticipation of information systems upgrade | (0.2%) | (0.5%) |
| **Net Sales increase** | **3.5%** | **4.7%** |

(1) On June 28, 2011, the Company acquired the BATISTE dry shampoo product line. Net sales of the acquired product line subsequent to the acquisition are included in the Company’s results.

For the three months ended September 30, 2012, the volume change reflects increased sales of products in both the Consumer Domestic and Consumer International segments partially offset by unfavorable product mix and pricing in Consumer Domestic. The Specialty Products Division (the “SPD”) had lower sales of products in the current quarter, partially offset by price increases. For the nine months ended September 30, 2012, the volume change primarily reflects increased sales of products in both Consumer Domestic and Consumer International, partially offset by unfavorable product mix and pricing in these segments. Sales in the first quarter of 2012 were negatively impacted due to a timing shift in customer orders from the first quarter of 2012 to the fourth quarter of 2011 in anticipation of the January 1, 2012 information systems upgrade in the United States.

#### Operating Costs

The Company’s gross profit was $327.5 million for the quarter ended September 30, 2012, a $17.6 million increase as compared to the same period in 2011. The gross profit increase was primarily attributable to higher sales volumes and contributions from the acquired product line, in-house production of unit dose detergent and the ramp-up of the Company’s new manufacturing and distribution facility in Victorville, California (the “Victorville Facility”), partially offset by the unfavorable effect of foreign exchange rates. In addition, commodity costs were higher in the quarter, but were largely offset by the effect of productivity programs. For the nine month period ended September 30, 2012, gross profit increased $35.0 million to $933.0 million. The increase in gross profit was due primarily to the higher sales volumes and acquired businesses partially offset by unfavorable pricing and mix, higher commodity costs that were partially offset by productivity improvement programs and unfavorable foreign exchange rates. Gross margin increased 100 basis points to 45.2% in the third quarter as compared to 44.2% in the same quarter of 2011. This increase is primarily due to the items noted for gross profit changes, offset by unfavorable product mix, with net sales for lower margin Consumer Domestic household products increasing by 7.6% and net sales of higher margin personal care products decreasing by 0.7%. Gross margin decreased 30 basis points to 44.2% in the first nine months of 2012 as compared to 44.5% in the same period in 2011 due to higher commodity costs and product mix, partially offset by productivity programs.

Marketing expenses for the third quarter of 2012 were $92.2 million, an increase of $0.4 million as compared to the same period in 2011. Marketing expenses as a percentage of net sales were 12.7% and 13.1% in the third quarter of 2012 and 2011, respectively. The effect of favorable foreign exchange rates was offset by expenses in support of new products. Marketing expenses for the first nine months of 2012 were $248.6 million, an increase of $0.1 million as compared to the same period in 2011 due primarily to the same factors as those applicable to the third quarter of 2012. Marketing expenses as a percentage of net sales were 11.8% in the first nine months of 2012 as compared to 12.3% in the same period in 2011.

Selling, general and administrative (“SG&A”) expenses were $89.9 million in the third quarter of 2012, a decrease of $1.9 million as compared to the same period in 2011. SG&A expenses were lower due to lower legal expenses, favorable foreign exchange rates, and lower costs in support of the Company’s information system upgrade. SG&A expenses as a percentage of net sales were 12.4% in the third quarter of 2012 compared to 13.1% in the third quarter of 2011. SG&A expenses for the first nine months of 2012 were $273.9 million, a decrease of $0.4 million as compared to the same period in 2011 due to lower legal expenses and favorable foreign exchange rates partially offset by higher costs for salaries and fringe benefits.

#### Other Income and Expenses

Equity in earnings of affiliates decreased by $0.5 million and $1.0 million for the three and nine month periods ended September 30, 2012, as compared to the same periods in 2011. The decrease is primarily due to costs related to the start-up of the Natronx Technologies LLC (“Natronx”) joint venture.

Interest expense in the three and nine month periods ended September 30, 2012 increased $0.4 million and $0.2 million respectively, compared to the same periods in 2011. The Company’s outstanding debt during the first nine months of 2012 consisted primarily of fixed rate obligations under its 3.35% senior notes due 2015. The issuance of the Company’s 2.875% Senior Notes borrowing and the increase in commercial paper at the end of the third quarter did not have a material impact on interest expense.

#### Taxation

The effective tax rate in the three and nine month periods ended September 30, 2012 was 35.7% and 34.8% respectively, compared to 36.8% and 34.7% respectively, in the same periods in 2011. The tax rate in the nine month period ended September 30, 2012 was favorably affected by the settlement of an IRS audit in the first quarter. The effective tax rate in the nine month period ended September 30, 2011 reflects a deferred income tax benefit of $6.1 million relating to New Jersey’s corporate tax reform legislation enacted in April 2011. The 2012 annual effective tax rate is projected to be approximately 35%.

### Segment results

The Company operates three reportable segments: Consumer Domestic, Consumer International and Specialty Products Division (“SPD”). These segments are determined based on differences in the nature of products and organizational and ownership structures. The Company also has a Corporate segment.

| Segment | Products |
| --- | --- |
| Consumer Domestic | Household and personal care products |
| Consumer International | Primarily personal care products |
| SPD | Specialty chemical products |

The Corporate segment income consists of equity in earnings (losses) of affiliates. The Company had 50% ownership interests in Armand Products Company (“Armand”), The ArmaKleen Company (“Armakleen”) and a one-third ownership interest in Natronx LLC (“Natronx”) as of September 30, 2012. The Company’s equity in earnings or losses of Armand, ArmaKleen and Natronx for the three and nine months ended September 30, 2012 and September 30, 2011, are included in the Corporate segment.

Some of the subsidiaries that are included in the Consumer International segment manufacture and sell personal care products to the Consumer Domestic segment. These sales are eliminated from the Consumer International segment results set forth below.

Segment Net Sales and Income Before Income Taxes for the three and nine month periods ended September 30, 2012 and September 30, 2011 were as follows:

*(In millions)*

| Net Sales(1) | Consumer Domestic | Consumer International | SPD | Corporate | Total |
| --- | ---: | ---: | ---: | ---: | ---: |
| **Third Quarter 2012** | **$530.4** | **$131.1** | **$63.7** | **$0.0** | **$725.2** |
| Third Quarter 2011 | 506.1 | 128.5 | 66.4 | 0.0 | 701.0 |
| **First Nine Months of 2012** | **$1,547.5** | **$373.8** | **$190.9** | **$0.0** | **$2,112.2** |
| First Nine Months of 2011 | 1,459.5 | 364.1 | 194.6 | 0.0 | 2,018.2 |
| **Income Before Income Taxes(2)** |  |  |  |  |  |
| **Third Quarter 2012** | **$116.6** | **$16.0** | **$11.0** | **$2.4** | **$146.0** |
| Third Quarter 2011 | 99.6 | 14.7 | 8.8 | 2.9 | 126.0 |
| **First Nine Months of 2012** | **$324.9** | **$52.6** | **$27.5** | **$7.3** | **$412.3** |
| First Nine Months of 2011 | 298.5 | 47.3 | 22.6 | 8.2 | 376.6 |

(1) Intersegment sales from Consumer International to Consumer Domestic, which are not reflected in the table, were $0.1 million and $1.2 million for the quarters ended September 30, 2012 and September 30, 2011, respectively, and were $1.9 million and $3.7 million for the nine months ended September 30, 2012 and September 30, 2011, respectively.

(2) In determining Income before Income Taxes, interest expense, investment earnings, and other income (expense) were allocated among the segments based upon each segment’s relative operating profit.

Product line sales to external customers for the three and nine months ended September 30, 2012 and September 30, 2011 were as follows:

*(In millions)*

|  | Three Months Ended September 30, 2012 | September 30, 2011 | Nine Months Ended September 30, 2012 | September 30, 2011 |
| --- | ---: | ---: | ---: | ---: |
| Household Products | **$360.4** | $335.0 | **$1,054.2** | $952.1 |
| Personal Care Products | **170.0** | 171.1 | **493.3** | 507.4 |
| Total Consumer Domestic | **530.4** | 506.1 | **1,547.5** | 1,459.5 |
| Total Consumer International | **131.1** | 128.5 | **373.8** | 364.1 |
| Total SPD | **63.7** | 66.4 | **190.9** | 194.6 |
| **Total Consolidated Net Sales** | **$725.2** | $701.0 | **$2,112.2** | $2,018.2 |

### Consumer Domestic

Consumer Domestic net sales in in the third quarter of 2012 were $530.4 million, an increase of $24.3 million or 4.8% as compared to the third quarter of 2011. Consumer Domestic net sales for the nine months ended September 30, 2012 were $1,547.5 million, an increase of $88.0 million or 6.0% as compared to the same period in 2011. The components of the net sales change are the following:

| Net Sales - Consumer Domestic | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 |
| --- | ---: | ---: |
| Product volumes sold | 5.2% | 9.0% |
| Pricing / Product mix | (0.4%) | (2.4%) |
| Sales in anticipation of information systems upgrade | 0.0% | (0.6%) |
| **Net Sales increase** | **4.8%** | **6.0%** |

In the third quarter of 2012, the increase in net sales principally reflects higher sales of ARM & HAMMER liquid laundry detergent, XTRA liquid laundry detergent, ARM & HAMMER cat litter, OXI CLEAN laundry additive, and the recently introduced ARM & HAMMER CRYSTAL BURST unit dose laundry detergent. These increases were partially offset by lower sales of ARM & HAMMER powder laundry detergent, SPINBRUSH battery-operated toothbrushes, ANSWER diagnostic kits and ARRID deodorant. The increase in net sales for the nine months ended September 30, 2012 was due primarily to the same factors as those applicable to the third quarter of 2012. Sales in the first quarter of 2012 were negatively impacted due to a timing shift in customer orders from the first quarter of 2012 to the fourth quarter of 2011 in anticipation of the January 1, 2012 information systems upgrade in the United States.

Consumer Domestic income before income taxes for the third quarter of 2012 was $116.6 million, a $17.0 million increase as compared to the third quarter of 2011. The increase is due to the impact of higher product volumes sold, increases in cat litter prices, new product launches in the personal care business and reduction in retailer slotting costs. Higher commodity and manufacturing costs were more than offset by manufacturing cost savings programs. SG&A costs were also higher principally due to higher salaries and fringe benefits. For the nine month period ended September 30, 2012, income before income taxes was $324.9 million, a $26.5 million increase as compared to the first nine months of 2011. The increase is due primarily to the impact of higher sales volumes, partially offset by the effect of unfavorable product mix and pricing and higher SG&A costs. Higher commodity and manufacturing costs were largely offset by productivity gains.

### Consumer International

Consumer International net sales were $131.1 million in the third quarter of 2012, an increase of $2.6 million or 2.0% as compared to the same period in 2011. Consumer International net sales in the first nine months of 2012 were $373.8 million, an increase of $9.7 million or 2.7% as compared to the same period in 2011. The components of the net sales change are the following:

| Net Sales - Consumer International | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 |
| --- | ---: | ---: |
| Product volumes sold | 6.6% | 4.1% |
| Pricing / Product mix | 0.1% | (0.5%) |
| Foreign exchange rate fluctuations | (5.3%) | (4.7%) |
| Acquired product lines (1) | 1.9% | 4.2% |
| Sales in anticipation of information systems upgrade | (1.3%) | (0.4%) |
| **Net Sales increase** | **2.0%** | **2.7%** |

(1) On June 28, 2011, the Company acquired the BATISTE dry shampoo product line. Net sales of the acquired product line subsequent to the acquisition are included in the Company’s results.

Higher sales volumes in the third quarter of 2012 are due to higher sales in Europe, Australia, Mexico and U.S. Exports. Higher sales volumes in the first nine months of 2012 occurred principally in Canada, Australia and Mexico. Higher U.S. exports also contributed to the nine month sales increase.

Consumer International income before income taxes was $16.0 million in the third quarter of 2012, an increase of $1.3 million compared to the same period in 2011. Higher profits are attributable to higher volumes, contribution from the Batiste acquisition, partially offset by higher commodity costs and unfavorable foreign exchange rates. For the first nine months of 2012, income before income taxes was $52.6 million, a $5.3 million increase as compared to the first nine months of 2011, reflecting higher sales volume and contribution from the Batiste acquisition, partially offset by higher marketing expenses and unfavorable pricing and product mix.

### Specialty Products

Specialty Products net sales were $63.7 million for the third quarter of 2012, a decrease of $2.7 million, or 4.0% as compared to the same period in 2011. Specialty Products net sales were $190.9 million for the first nine months of 2012, a decrease of $3.7 million, or 1.9% as compared to the same period in 2011. The components of the net sales change are the following:

| Net Sales - SPD | Three Months Ended September 30, 2012 | Nine Months Ended September 30, 2012 |
| --- | ---: | ---: |
| Product volumes sold | (4.7%) | (2.2%) |
| Pricing / Product mix | 3.8% | 3.3% |
| Foreign exchange rate fluctuations | (3.1%) | (2.5%) |
| Sales in anticipation of information systems upgrade | 0.0% | (0.5%) |
| **Net Sales (decrease)** | **(4.0%)** | **(1.9%)** |

The sales volume decrease in the third quarter of 2012 reflects less product sales of certain animal nutrition products, partially offset by favorable pricing. In addition, unfavorable foreign exchange rates contributed to lower sales. The decrease in net sales for the nine months ended September 30, 2012 reflect the same factors as in the third quarter of 2012. Sales in the first quarter of 2012 were negatively impacted due to a timing shift in customer orders from the first quarter of 2012 to the fourth quarter of 2011 in anticipation of the January 1, 2012 information systems upgrade in the United States.

Specialty Products income before income taxes was $11.0 million in the third quarter of 2012, an increase of $2.2 million as compared to the same period in 2011, and was $27.4 million for the first nine months of 2012, an increase of $4.8 million as compared to the same period in 2011. The increase in the third quarter income before income taxes is primarily a result of slightly higher selling prices and lower SG&A expenses, partially offset by unfavorable foreign exchange rates and higher raw material costs. The increase in income before income taxes for the first nine months of 2012 primarily reflects higher selling prices and lower SG&A expenses, partially offset by higher raw material costs of certain animal nutrition and performance products and unfavorable foreign exchange rates.

### Liquidity and Capital Resources

As of September 30, 2012, the Company had $891.2 million in cash (of which $650 million was in escrow for the acquisition of Avid Health), approximately $250 million available through its revolving credit facility under its principal credit agreement (the “Credit Agreement”) and its commercial paper program, and a commitment increase feature under the Credit Agreement that enables the Company to borrow up to an additional $500 million, subject to lending commitments of the participating lenders and certain conditions as described in the Credit Agreement. To preserve its cash resources, the Company invests its cash primarily in prime money market funds.

As of September 30, 2012, the amount of cash and cash equivalents, included in the Company’s consolidated cash, that was held by foreign subsidiaries was approximately $146.1 million. If these funds are needed for operations in the U.S. the Company will be required to accrue and pay taxes in the U.S. to repatriate these funds. However, the Company’s intent is to permanently reinvest these funds outside the U.S., and the Company’s current plans do not indicate a need to repatriate the funds to support operations in the U.S.

On September 26, 2012, the Company closed an underwritten public offering of $400 million aggregate principal amount of 2.875% Senior Notes (the “Notes”). The Notes were issued under the second supplemental indenture (the “Second Supplemental Indenture”), dated September 26, 2012, to the indenture dated December 15, 2010, between the Company and The Bank of New York Mellon Trust Company, N.A., as trustee. Interest on the 2.875% Notes is payable semi-annually, beginning April, 2013. The Notes will mature on October 1, 2022, unless earlier retired or redeemed pursuant to the terms of the Second Supplemental Indenture. Also, in late September, the Company issued $220 million of Commercial Paper. At the time, the Company had $30 million of Commercial Paper outstanding. The Company used the $250 million from commercial paper issuances, along with the $400 million of Notes, to purchase Avid Health on October 1, 2012.

The current economic environment presents risks that could have adverse consequences for the Company’s liquidity. (See “Economic conditions could adversely affect our business” under “Risk Factors” in Item 1A of the Company’s Form 10-K). The Company does not anticipate that current economic conditions will adversely affect its ability to comply with the financial covenants in its principal credit facilities because the Company currently is, and anticipates that it will continue to be, in compliance with the minimum interest coverage ratio requirement and the maximum leverage ratio requirement under the Credit Agreement. These financial ratios are discussed in more detail in this section under “Certain Financial Covenants.”

On February 1, 2012, the Board of Directors increased the Company’s regular quarterly dividend from $0.17 per share to $0.24 per share, equivalent to an annual dividend rate of $0.96 per share. The higher dividend raises the Company’s annualized dividend payout from approximately $97 million to approximately $137 million.

On October 31, 2012, the Company’s Board of Directors authorized a new share repurchase program, under which the Company may purchase up to an additional $300 million of the Company’s common stock. The previous authorization announced in August 2011 has approximately $20 million remaining for use in the repurchase of the Company’s shares. Under the new program, shares may be repurchased from time to time in the open market, in privately negotiated transactions or otherwise, subject to market conditions, and corporate and legal requirements. There is no expiration date on the stock repurchase authorization and the Company is not obligated to acquire any specific number of shares. As of October 30, 2012, approximately 140 million shares of the Company’s common stock were outstanding.

On August 4, 2011, the Company’s Board of Directors authorized the repurchase of up to $300 million of the Company’s Common Stock. Purchases may be made from time to time in the open market, in privately negotiated transactions or otherwise, subject to market conditions, corporate and legal requirements and other factors. There is no expiration date on the stock repurchase authorization, and the Company is not obligated to acquire any specific number of shares. The Company began purchasing its stock under this authorization on October 11, 2011. The Company purchased approximately 2.2 million shares at a cost of $110.0 million in the second quarter of 2012. As of September 30, 2012, the Company has purchased an aggregate of 5.9 million shares at a cost of approximately $280 million under the repurchase authorization and does not anticipate making any additional purchases for the balance of 2012.

The Company anticipates that its cash from operations, together with its current borrowing capacity, will be sufficient to meet its capital expenditure program costs, which are expected to be approximately $75 million in 2012, pay dividends at the latest approved rate and meet its contractual obligation to contribute up to approximately $4.8 million to Natronx for additional capital development.

#### Net Debt

The Company had outstanding total debt of $903.8 million and cash of $891.2 million, including $650 million in escrow, at September 30, 2012, resulting in net debt of $12.6 million at September 30, 2012. Excluding the amount held in escrow, net debt was $662.6 million. This compares to total debt of $252.3 million and cash of $251.4 million, resulting in net debt of $0.9 million at December 31, 2011. Net debt is defined as total debt less cash.

#### Cash Flow Analysis

*(In millions)*

|  | Nine Months Ending September 30, 2012 | September 30, 2011 |
| --- | ---: | ---: |
| Net cash provided by operating activities | **$315.9** | $319.2 |
| Net cash used in investing activities | **$(711.0)** | $(104.9) |
| Net cash provided by (used in) financing activities | **$381.3** | $(129.1) |

**Net Cash Provided by Operating Activities –** The Company’s net cash provided by operating activities in the first nine months of 2012 decreased $3.3 million to $315.9 million as compared to the same period in 2011. The decrease was primarily due to higher tax payments in 2012 as a result of favorable tax depreciation rules in 2011 offset by higher net income.

**Net Cash Used in Investing Activities –** Net cash used in investing activities during the first nine months of 2012 was $711.0 million, principally reflecting $650.0 million of cash in escrow for acquiring Avid Health, $49.6 million of property, plant and equipment expenditures, relating in part to the Victorville Facility, and a $9.7 million investment in Natronx.

**Net Cash Provided by Financing Activities –** Net cash provided by financing activities during the first nine months of 2012 was $381.3 million, reflecting $399.6 million of Notes (net of discount) and $250.0 million of commercial paper issued in connection with the acquisition of Avid Health, $34.5 million of proceeds and tax benefits from stock option exercises, partially offset by $200.4 million of common stock repurchases, $101.0 million of cash dividends, and deferred financing costs of $3.4 million.

### Certain Financial Covenants

“Consolidated EBITDA” (referred to below as “Adjusted EBITDA”) is a component of the financial covenants contained in, and is defined in, the Company’s Credit Agreement. Financial covenants include a leverage ratio (total debt to Adjusted EBITDA) and an interest coverage ratio (Adjusted EBITDA to total interest expense), which if not met, could result in an event of default and trigger the early termination of the Credit Agreement. Adjusted EBITDA may not be comparable to similarly titled measures used by other entities and should not be considered as an alternative to cash flows from operating activities, which is determined in accordance with accounting principles generally accepted in the United States. The Company’s leverage ratio for the 12 months ended September 30, 2012 was 1.5, which is below the maximum of 3.25 permitted under the Credit Agreement, and the interest coverage ratio for the twelve months ended September 30, 2012 was 69.6, which is above the minimum of 3.00 required under the Credit Agreement. The maximum leverage ratio under the Credit Agreement will increase in the fourth quarter of 2012 to 3.50 as a result of the Avid Health acquisition.

### New Accounting Pronouncements

During the second quarter of 2012, the Company adopted new guidance on reporting and presentation of comprehensive income. The new guidance requires an entity to report comprehensive income either in a single continuous financial statement (together with components of net income) or in a separate financial statement immediately following the income statement. The Company elected to provide consolidated statements of income and consolidated statements of comprehensive income in two separate but consecutive statements. Refer to the Condensed Consolidated Statements of Income, Condensed Consolidated Statements of Comprehensive Income and related Note 12 for additional information. The new requirements did not have an impact on the Company’s financial position, results of operations or cash flows.

On July 27, 2012, the Financial Accounting Standards Board (FASB) issued new guidance to simplify how entities test indefinite-lived intangible assets for impairment. The new guidance allows an entity to first assess qualitative factors to determine whether it is necessary to perform a quantitative indefinite-lived intangible asset impairment test. The new guidance is effective for annual indefinite-lived intangible asset impairment tests to be performed in fiscal year 2013, with early adoption permitted. The Company does not expect the adoption to have any impact on its consolidated financial position, results of operations or cash flows.

There have been no other accounting pronouncements issued but not yet adopted by the Company which are expected to have a material impact on the Company’s financial position, results of operations or cash flows. Other accounting pronouncements that became effective during the nine months ended September 30, 2012 did not have an impact on the Company’s financial position, results of operations or cash flows.

## Market risk

As filed, 2,773 characters.

### Market risk

#### Interest Rate Risk

The Company had outstanding total debt at September 30, 2012 of $903.8 million, of which 72% has a fixed weighted average interest rate of 3.06%, and the remaining 28% constituted principally commercial paper issued by the Company that currently has an interest rate of less than 0.5%.

#### Diesel Fuel Hedge

The Company uses independent freight carriers to deliver its products. These carriers charge the Company a basic rate per mile that is subject to a mileage surcharge for diesel fuel price increases. During 2011 and 2012, the Company entered into hedge agreements with financial counterparties to mitigate the volatility of diesel fuel prices and related fuel surcharges, and not to speculate in the future price of diesel fuel. Under the hedge agreements, the Company agreed to pay a fixed price per gallon of diesel fuel determined at the time the agreements were executed and to receive a floating rate payment reflecting the variable common carriers’ mileage surcharge. The agreements cover approximately 54% of the Company’s estimated remaining diesel fuel requirements for 2012 and 36% of the Company’s total 2013 estimated diesel fuel requirements. These agreements qualify for hedge accounting. Therefore, changes in the fair value of diesel fuel hedge agreements are recorded in Accumulated Other Comprehensive Income on the balance sheet.

#### Foreign Currency

The Company is subject to exposure from fluctuations in foreign currency exchange rates, primarily U.S. Dollar/Euro, U.S. Dollar/British Pound, U.S. Dollar/Canadian Dollar, U.S. Dollar/Mexican Peso, U.S. Dollar/Australian Dollar, U.S. Dollar/Brazilian Real and U.S. Dollar/Chinese Yuan.

The Company, from time to time, enters into forward exchange contracts to reduce the impact of foreign exchange rate fluctuations related to anticipated but not yet committed intercompany sales or purchases denominated in the U.S. dollar, Canadian dollar, British pound and Euro. The Company entered into forward exchange contracts to protect it from the risk that, due to changes in currency exchange rates, it would be adversely affected by net cash outflows.

#### Equity Derivatives

The Company has entered into equity derivative contracts covering its own stock in order to minimize its liability, resulting from changes in quoted fair values of Company stock, to participants under its Executive Deferred Compensation Plan who have investments under that plan in a notional Company stock fund. The contracts are settled in cash. Since the equity derivatives do not qualify for hedge accounting, the Company is required to mark the agreements to market throughout the life of the agreements and record changes in fair value in the consolidated statement of income.

## Controls and procedures

As filed, 4,450 characters.

a) Evaluation of Disclosure Controls and Procedures

The Company’s management, with the participation of the Company’s Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) at the end of the period covered by this report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures as of the end of the period covered by this report are effective to provide reasonable assurance that the information required to be disclosed by the Company in reports filed under the Exchange Act are (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (ii) accumulated and communicated to the Company’s management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding the disclosure.

b) Change in Internal Control over Financial Reporting

No change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the Company’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

### CAUTIONARY NOTE ON FORWARD-LOOKING INFORMATION

This Report contains forward-looking statements, including, among others, statements relating to sales and earnings growth, the effect of product mix and volume growth, earnings per share, gross margin changes, trade and marketing spending, marketing expense as a percentage of net sales, cost savings programs, the Company’s hedge programs, the impact of foreign exchange and commodity fluctuations, the Company’s stock repurchase program, the impact of acquisitions, including Avid Health, capital expenditures, the sales impact related to the Company’s information systems upgrade, the effective tax rate, the impact of tax audits, tax changes and the lapse of applicable statutes of limitations, facility restructuring charges, environmental matters, the effect of the credit environment on the Company’s liquidity and capital expenditures, the Company’s fixed rate debt, the Company’s commercial paper program, sufficiency of cash flows from operations, the Company’s current and anticipated future borrowing capacity to meet capital expenditure program costs, payment of dividends, expected cash contributions to pension plans, investments in the Natronx joint venture, completion of the Company’s new corporate office building, transition costs relating to the start up of the Victorville Facility and transition of operations at the Company’s Green River, Wyoming facility. These statements represent the intentions, plans, expectations and beliefs of the Company, and are subject to risks, uncertainties and other factors, many of which are outside the Company’s control and could cause actual results to differ materially from such forward-looking statements, including a decline in market growth and consumer demand (as a result of, among other things, political, economic and marketplace conditions and events); unanticipated increases in raw material and energy prices; adverse developments affecting the financial condition of major customers and suppliers; competition; the impact of trade customer actions in response to changes in consumer demand and the economy, including increasing shelf space of private label products; consumer reaction to new product introductions and features; disruptions in the banking system and financial markets, foreign currency exchange rate fluctuations, the impact of Hurricane Sandy on the Company and its customers and suppliers, including third party information technology service providers, and the outcome of contingencies, including litigation, pending regulatory proceedings and environmental remediation.

The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the U.S. federal securities laws. You are advised, however, to consult any further disclosures we make on related subjects in our filings with the U.S. Securities and Exchange Commission.

## Risk factors

As filed, 10,259 characters.

In addition to the other information set forth in this report, you should carefully consider the Risk Factors discussed in Item 1A, “Risk Factors” in the Form 10-K, which could materially affect the Company’s business, financial condition or future results. There have been no material changes to the disclosures relating to this item from those set forth in the Form 10-K except with respect to the risk factors below, which are amended and restated in their entirety as follows:

- **We may make acquisitions that result in dilution to our current stockholders or increase our indebtedness, or both. In addition, acquisitions that are not properly integrated or are otherwise unsuccessful could strain or divert our resources.**

We have made several acquisitions in recent years, including businesses previously operated by Del Pharmaceuticals, Inc. and Orange Glo International, Inc., the SIMPLY SALINE nasal moisturizer product line, the FELINE PINE natural cat litter product line and the BATISTE dry shampoo product line. Most recently, we completed the acquisition of all of the outstanding common stock of Avid Health, Inc., a manufacturer of gummy form vitamins and supplements. We may make additional acquisitions or substantial investments in complementary businesses or products in the future. Any acquisitions or investments, including the Avid Health acquisition, the integration of which is still ongoing, could entail various risks, including the difficulty of integrating the operations and personnel of the acquired businesses or products, the potential disruption of our ongoing business and, generally, our potential inability to obtain the desired financial and strategic benefits from the acquisition or investment. The risks associated with assimilation are increased to the extent we acquire businesses that have stand-alone operations that cannot easily be integrated or operations or sources of supply outside of the United States and Canada, for which products are manufactured locally by third parties. These factors could harm our financial condition and operating results. Any future acquisitions or investments could result in substantial cash expenditures, the issuance of new equity by us or the incurrence of additional debt and contingent liabilities. In addition, any potential acquisitions or investments, whether or not ultimately completed, could divert the attention of management and resources from other matters that are critical to our operations.

- **Compliance by us and certain of our suppliers with various existing and future regulations in the countries in which we operate could expose us to increased costs and other adverse consequences.**

The manufacturing, processing, formulation, packaging, labeling, marketing and sale of our products are subject to regulation by federal agencies, including the Food and Drug Administration (the “FDA”), the Federal Trade Commission (“FTC”) and the Consumer Product Safety Commission. In addition, our operations are subject to the oversight of the Environmental Protection Agency, the Occupational Safety and Health Administration and the National Labor Relations Board. Our activities are also regulated by various agencies of the states, localities and foreign countries in which our products are sold.

In particular, the FDA regulates the formulation, safety, manufacturing, packaging, labeling and distribution of condoms, home pregnancy and ovulation test kits, battery operated toothbrushes, over-the-counter pharmaceuticals and dietary supplements, including vitamins. The FDA also exercises oversight over cosmetic products such as depilatories. In addition, under a memorandum of understanding between the FDA and the FTC, the FTC has jurisdiction with regard to the promotion and advertising of these products, and the FTC regulates the promotion and advertising of our other products as well. As part of its regulatory authority, the FDA may periodically conduct inspections of the physical facilities, machinery, processes and procedures that we use to manufacture regulated products and may observe compliance issues that would require us to make certain changes in our manufacturing facilities and processes. The failure of a facility to be in compliance may lead to regulatory action against the products made in that facility, including seizure, injunction or recall, as well as to possible action against the owner of the facility/manufacturer. We may be required to make additional expenditures to address these issues or possibly stop selling certain products until the compliance issue has been remediated. As a result, our business could be adversely affected.

For example, the FDA issued a warning letter to us, dated May 16, 2011 (the “Warning Letter”), following an inspection of our Princeton, New Jersey headquarters. The Warning Letter stated that our medical device reporting procedure did not properly identify all required reportable events. The Warning Letter also criticized our proposals for addressing inadequacies previously identified by the FDA as to our complaint handling process. In response, we proposed several corrective actions that were accepted by the FDA, and engaged in further discussions with the FDA to resolve the issue relating to our complaint handling process. In addition, partly in response to the FDA’s stated concerns, we made product and labeling changes in 2011 and issued a December 2011 safety notice advising consumers about the proper use of SPINBRUSH toothbrushes to avoid injuries associated with improper use of the product.

On February 13, 2012, at the conclusion of an inspection of our Princeton facility, the FDA issued a Notice of Inspectional Observations (also known as a “483 report”), containing several observations, including a repeat of an issue identified in a previous 483 report and in the Warning Letter, namely a failure to properly identify all required reportable events. In addition, the 483 report addressed inadequacies in procedures and processes related to corrective and preventive actions, complaint handling, maintenance of a quality system record, and establishment of records of acceptable suppliers. On February 16, 2012, the FDA issued a safety communication warning consumers “of serious injuries and potential hazards associated with the use of SPINBRUSH.” On March 8, 2012, we met with the FDA to present our completed and continuing efforts to address their concerns and to assure them of our ongoing commitment to meet all regulatory requirements. On June 27, 2012, the FDA closed out the Warning Letter, stating it was satisfied with our responses and actions to address all noted issues. We continue our work on strengthening our quality systems to ensure continued compliance with regulatory requirements.

There is no assurance that the FDA will not take future enforcement action in connection with the foregoing matters, or that additional safety notices or recalls of our SPINBRUSH product will not be required. Either additional enforcement action, or additional safety notices or recalls, if they were to occur, could have a material adverse effect on our financial condition, results of operations and cash flow.

Likewise, any future determination by the FDA or a similar foreign agency that our products or quality systems do not comply with applicable regulations could result in future compliance activities, including product recalls, import detentions, injunctions preventing the shipment of products, or other enforcement actions (and associated adverse publicity) that could have a material adverse effect on our financial condition, results of operations and cash flow.

From time to time, Congress, the FDA, the FTC or other federal, state, local or foreign legislative and regulatory authorities may impose additional laws or regulations that apply to us, repeal laws or regulations that we consider favorable to us or impose more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals or interpretations or to predict the effect additional governmental regulation, when and if it occurs, would have on our business in the future. Such developments could require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, expanded adverse event reporting or other new requirements. Any such developments could increase our costs significantly and could have a material adverse effect on our business, financial condition and results of operations.

- **Our operations and the operations of our third party manufacturers, suppliers and customers may be subject to disruption from events beyond our or their control.**

Our operations, as well as the operations of our third party manufacturers, suppliers and customers may be subject to disruption from a variety of causes, including work stoppages, financial difficulties, acts of war, terrorism, pandemics, fire, earthquake, flooding or other natural disasters. If a major disruption were to occur at our operations, it could result in harm to people or the natural environment, delays in shipments of products to customers or suspension of operations, any of which could have a material adverse effect on our business. Similar consequences may result with regard to disruptions in the operations of our third party manufacturers, suppliers or customers, some of which could have a material adverse effect upon our business.

As a result of Hurricane Sandy, certain of the Company’s operations and the operations of certain of its customers and suppliers, including third party information technology service providers, were affected by the loss of electricity and other disruptions to our and their businesses. While we are currently unable to quantify the financial impact of such losses and disruptions, it is possible that they could have a material adverse effect on the Company’s business, financial condition, results of operations and cash flows.

Filed Nov 5, 2012.
Source: SEC EDGAR, the filing index for accession 0001193125-12-451493. Last ingested by Listed: Nov 14, 2026, 21:34 ET. No prices; not investment advice.
